FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Phase III

SPOTLIGHT: FDA OKs expanded access for stem cell therapy

Tools


Osiris Therapeutics has won approval for an expanded access treatment program for Prochymal, making the Phase III stem cell therapy for graft-vs-host-disease available to children. Osiris release

More stories about Phase III  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.